Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress

PUBT · 1d ago
Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress
  • Purple Biotech highlighted new preclinical data on cancer candidate IM1240, already presented at the EACR 2026 Annual Congress.
  • The results supported a differentiated anti-tumor profile, favorable safety and pharmacokinetics, and a broad therapeutic window.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.